Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data

Figure 4 The expression levels of Beclin1 and 4E-binding protein 1 are independent prognostic factors for overall survival of advanced colorectal cancer patients initially treated with cetuximab-containing chemotherapy. A: The median overall survival (OS) of patients with low and high Beclin1 expression (low expression was defined as an immunohistochemistry score ≤ 0, and high expression was defined as a score > 0) was 19.65 mo vs 37.82 mo, respectively. B: The median OS of patients with low and high 4E-BP1 expression (low expression was defined as an immunohistochemistry score ≤ 0, and high expression was defined as a score > 0) was 64.82 mo vs 23.66 mo, respectively. OS: Overall survival; 4E-BP1: 4E-binding protein 1.